GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Graham Number

Cleo Diagnostics (ASX:COV) Graham Number : A$N/A (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-24), the stock price of Cleo Diagnostics is A$0.17. Cleo Diagnostics's graham number for the quarter that ended in Dec. 2023 was A$N/A. Therefore, Cleo Diagnostics's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Cleo Diagnostics's Graham Number or its related term are showing as below:

ASX:COV's Price-to-Graham-Number is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.81
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Cleo Diagnostics Graham Number Historical Data

The historical data trend for Cleo Diagnostics's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Graham Number Chart

Cleo Diagnostics Annual Data
Trend Jun23
Graham Number
-

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
Graham Number - - -

Competitive Comparison of Cleo Diagnostics's Graham Number

For the Medical Devices subindustry, Cleo Diagnostics's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's Price-to-Graham-Number Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Price-to-Graham-Number falls into.



Cleo Diagnostics Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Cleo Diagnostics's Graham Number for the fiscal year that ended in Jun. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-0.031*-0.066)
=N/A

Cleo Diagnostics's Graham Number for the quarter that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*0.079*-0.049)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics  (ASX:COV) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Cleo Diagnostics's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2023 )
=0.17/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Cleo Diagnostics Graham Number Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines